Live Breaking News & Updates on ஃபேப் செயல்பாடுகள்|Page 4

Stay updated with breaking news from ஃபேப் செயல்பாடுகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FAB to buy Egyptian business of Lebanon's Bank Audi - News

FAB Egypt will be one of the largest foreign banks in Egypt by total assets once the acquisition is completed ....

Abu Dhabi , Abuz Aby , United Arab Emirates , Samir Hanna , Lebanon Bank Audi , Bahrain Bank , First Abu Dhabi Bank , Lebanon Blom Bank , Bank Audi , Bank Audi Egypt , Blom Bank , ஒன்றுபட்டது அரபு அமீரகங்கள் , சமீர் ஹன்னா , லெபனான் வங்கி ஆடி , பஹ்ரைன் வங்கி , லெபனான் ப்ளூம் வங்கி , வங்கி ஆடி , வங்கி ஆடி எகிப்து , ப்ளூம் வங்கி ,

UAE looks set for V-shaped economic recovery

FAB’s Global Investment Outlook report forecasts a good return to growth as economies emerge from Covid-19, but with a period of stabilisation bef. ....

United Arab Emirates , Abu Dhabi Commercial Bank , United States , Abu Dhabi , Abuz Aby , United Kingdom , Saudi Arabia , Khaleej Times , Hana Al Rostamani , Vijay Valecha , Monica Malik , Alain Marckus , Saad Maniar , Banking Group , Fitch Ratings , International Monetary Fund , Central Bank , First Abu Dhabi Bank , World Bank , European Union , Us Energy Information Administration , Investment Outlook , Dubai Expo , Chief Investment Officer , Century Financial , Investment Strategy ,

ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Cancer | Antibodies

Hits: 1063
First HER2 directed medicine approved for patients with gastric cancer in a decade
TOKYO, Japan & MUNICH, Germany & BASKING RIDGE, NJ USA I January 15, 2021 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s
ENHERTU
® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
In the U.S., gastric cancer is more frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving five years.
1,2 Approximately one in five gastric cancers are HER2 positive. ....

Baylor University , United States , South Korea , Dave Fredrickson , Ronan Kelly , Daiichi Sankyo , Ww Caruth Jr , Antoine Yver , National Cancer Institute , American Society Of Clinical Oncology , Drug Administration , I Daiichi Sankyo Company , Clinical Development Program , Charlesa Sammons Cancer Center , Oncology Research , Daiichi Sankyo Group , European Medicines Agency , Daiichi Sankyo Company Ltd , Immunology At Baylor University Medical Center , American Cancer Society , Patients With Previously Treated , Advanced Gastric Cancer , Statesi January , Daiichi Sankyo Company , Cancer Center , Baylor University Medical Center ,

UAE's FAB issues 1.5 billion yuan five-year bond

UAE s FAB issues 1.5 billion yuan five-year bond
SECTIONS
Last Updated: Jan 12, 2021, 03:21 PM IST
Share
Synopsis
The majority of investors comprised both onshore Taiwanese and Asian investors, and was well diversified amongst life insurers, banks, fund managers and securities houses, it said in a statement.
DUBAI: First Abu Dhabi Bank, UAE s biggest lender, said on Tuesday it has issued a 1.5 billion yuan ($232.05 million) five-year bond at 3.15%, the year s first yuan debt in the Formosa bond market.
The majority of investors comprised both onshore Taiwanese and Asian investors, and was well diversified amongst life insurers, banks, fund managers and securities houses, it said in a statement. ....

United Arab Emirates , Abu Dhabi , Abuz Aby , First Abu Dhabi Bank , Five Year Bond , ஒன்றுபட்டது அரபு அமீரகங்கள் , ஐந்து ஆண்டு பத்திரம் ,

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene | Antibodies

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene ....

United States , United Kingdom , Susanne Schaffert , China National Medical Products Administration , European Union , Beigene Ltd , Novartis Oncology , North America , Switzerlandi January , Hart Scott Rodino Antitrust Improvements , Therapeutic Antibodies , Antibody Drug Conjugates , Biosimilar Antibodies , Biosuperior Antibodies , Antibody Fragments , Domain Antibodies , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , ஐரோப்பிய தொழிற்சங்கம் , நோவர்த்திச் புற்றுநோயியல் , வடக்கு அமெரிக்கா , ஹார்ட் ஸ்காட் ரோடினோ நம்பிக்கையற்ற மேம்பாடுகள் , சிகிச்சை ஆன்டிபாடிகள் , களம் ஆன்டிபாடிகள் ,